Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GPVI-CD39
- Development stage
- Preclinical
- Lead developer
- AdvanceCOR
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
GPVI-CD39 is a bifunctional recombinant fusion protein being developed by AdvanceCOR for the treatment of acute arterial thrombosis and atherothrombotic conditions. The molecule consists of the extracellular domain of platelet glycoprotein VI (GPVI) linked to the Fc region of human IgG2 and the extracellular domain of the ectonucleotidase CD39 (also known as ADPase or NTPDase1). It operates via a dual mechanism: the GPVI domain targets and binds to collagen exposed at sites of vascular injury, thereby blocking collagen-mediated platelet activation, while the CD39 domain locally degrades adenosine diphosphate (ADP), preventing ADP-induced platelet aggregation and thrombus expansion. This lesion-directed approach is designed to concentrate antithrombotic activity at the site of plaque rupture, potentially reducing the risk of systemic bleeding complications compared to conventional antiplatelet agents.
- Other names
- GPVI-Fc-CD39GPVI-Fc-CD-39GPVI-Fc-CD 39GPVI-CD39 fusion proteinGPVI-CD-39 fusion proteinGPVI-CD 39 fusion protein
Beyond the preview
Go deeper on GPVI-CD39.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GPVI-CD39.